These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 24626203)

  • 1. Purine analog-like properties of bendamustine underlie rapid activation of DNA damage response and synergistic effects with pyrimidine analogues in lymphoid malignancies.
    Hiraoka N; Kikuchi J; Yamauchi T; Koyama D; Wada T; Uesawa M; Akutsu M; Mori S; Nakamura Y; Ueda T; Kano Y; Furukawa Y
    PLoS One; 2014; 9(3):e90675. PubMed ID: 24626203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The discovery and the development of bendamustine for the treatment of non-Hodgkin lymphoma.
    Munakata W; Tobinai K
    Expert Opin Drug Discov; 2016 Nov; 11(11):1123-1130. PubMed ID: 27598460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial.
    Rummel M; Kaiser U; Balser C; Stauch M; Brugger W; Welslau M; Niederle N; Losem C; Boeck HP; Weidmann E; von Gruenhagen U; Mueller L; Sandherr M; Hahn L; Vereshchagina J; Kauff F; Blau W; Hinke A; Barth J;
    Lancet Oncol; 2016 Jan; 17(1):57-66. PubMed ID: 26655425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytosine arabinoside potentiates the apoptotic effect of bendamustine on several B- and T-cell leukemia/lymphoma cells and cell lines.
    Castegnaro S; Visco C; Chieregato K; Bernardi M; Albiero E; Zanon C; Madeo D; Rodeghiero F
    Leuk Lymphoma; 2012 Nov; 53(11):2262-8. PubMed ID: 22530665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bendamustine: a review of its use in the management of chronic lymphocytic leukaemia, rituximab-refractory indolent non-Hodgkin's lymphoma and multiple myeloma.
    Hoy SM
    Drugs; 2012 Oct; 72(14):1929-50. PubMed ID: 22950536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The combination effects of bendamustine with antimetabolites against childhood acute lymphoblastic leukemia cells.
    Goto S; Goto H; Yokosuka T
    Int J Hematol; 2016 May; 103(5):572-83. PubMed ID: 26886449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Temsirolimus acts as additive with bendamustine in aggressive lymphoma.
    Zoellner AK; Weiglein T; Hutter G; Zimmermann Y; Cieplik HC; Hess G; Dreyling M
    Ann Hematol; 2016 Feb; 95(3):403-7. PubMed ID: 26658770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of YM155, a survivin suppressant, with bendamustine and rituximab: a new combination therapy to treat relapsed/refractory diffuse large B-cell lymphoma.
    Kaneko N; Mitsuoka K; Amino N; Yamanaka K; Kita A; Mori M; Miyoshi S; Kuromitsu S
    Clin Cancer Res; 2014 Apr; 20(7):1814-22. PubMed ID: 24486595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cytotoxic effects of bendamustine in combination with cytarabine in mantle cell lymphoma cell lines.
    Visco C; Castegnaro S; Chieregato K; Bernardi M; Albiero E; Zanon C; Madeo D; Rodeghiero F
    Blood Cells Mol Dis; 2012 Jan; 48(1):68-75. PubMed ID: 22036761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ricolinostat, a selective HDAC6 inhibitor, shows anti-lymphoma cell activity alone and in combination with bendamustine.
    Cosenza M; Civallero M; Marcheselli L; Sacchi S; Pozzi S
    Apoptosis; 2017 Jun; 22(6):827-840. PubMed ID: 28315173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma.
    Vacirca JL; Acs PI; Tabbara IA; Rosen PJ; Lee P; Lynam E
    Ann Hematol; 2014 Mar; 93(3):403-9. PubMed ID: 23955074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In AML cell lines Ara-C combined with purine analogues is able to exert synergistic as well as antagonistic effects on proliferation, apoptosis and disruption of mitochondrial membrane potential.
    Chow KU; Boehrer S; Napieralski S; Nowak D; Knau A; Hoelzer D; Mitrou PS; Weidmann E
    Leuk Lymphoma; 2003 Jan; 44(1):165-73. PubMed ID: 12691159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of bendamustine and entinostat synergistically inhibits proliferation of multiple myeloma cells via induction of apoptosis and DNA damage response.
    Cai B; Lyu H; Huang J; Wang S; Lee CK; Gao C; Liu B
    Cancer Lett; 2013 Jul; 335(2):343-50. PubMed ID: 23459296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bendamustine's emerging role in the management of lymphoid malignancies.
    Rummel MJ; Gregory SA
    Semin Hematol; 2011 Apr; 48 Suppl 1():S24-36. PubMed ID: 21530769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphoma.
    Martin P; Chen Z; Cheson BD; Robinson KS; Williams M; Rajguru SA; Friedberg JW; van der Jagt RH; LaCasce AS; Joyce R; Ganjoo KN; Bartlett NL; Lemieux B; VanderWalde A; Herst J; Szer J; Bar MH; Cabanillas F; Dodds AJ; Montgomery PG; Pressnail B; Ellis T; Smith MR; Leonard JP
    Br J Haematol; 2017 Jul; 178(2):250-256. PubMed ID: 28419413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Soluble Interleukin-2 Receptor and C-Reactive Protein with the Efficacy of Bendamustine Salvage Treatment for Indolent Lymphomas and Mantle Cell Lymphoma.
    Kawaguchi Y; Nakamaki T; Abe M; Baba Y; Murai S; Watanuki M; Arai N; Fujiwara S; Kabasawa N; Tsukamoto H; Uto Y; Ariizumi H; Yanagisawa K; Hattori N; Harada H; Saito B
    Acta Haematol; 2018; 139(1):12-18. PubMed ID: 29301121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma.
    Witzig TE; Nowakowski GS; Habermann TM; Goy A; Hernandez-Ilizaliturri FJ; Chiappella A; Vitolo U; Fowler N; Czuczman MS
    Ann Oncol; 2015 Aug; 26(8):1667-77. PubMed ID: 25712458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prolonged lymphocytopenia after bendamustine therapy in patients with relapsed or refractory indolent B-cell and mantle cell lymphoma.
    Saito H; Maruyama D; Maeshima AM; Makita S; Kitahara H; Miyamoto K; Fukuhara S; Munakata W; Suzuki T; Kobayashi Y; Taniguchi H; Tobinai K
    Blood Cancer J; 2015 Oct; 5(10):e362. PubMed ID: 26495859
    [No Abstract]   [Full Text] [Related]  

  • 19. Metabolism and mechanisms of action of bendamustine: rationales for combination therapies.
    Gandhi V
    Semin Oncol; 2002 Aug; 29(4 Suppl 13):4-11. PubMed ID: 12170425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bendamustine in the treatment of non-Hodgkin's lymphoma: results and future perspectives.
    Rummel MJ; Mitrou PS; Hoelzer D
    Semin Oncol; 2002 Aug; 29(4 Suppl 13):27-32. PubMed ID: 12170430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.